Regencell Bioscience Holdings Limited
RGC
$32.00
-$2.34-6.81%
NASDAQ
| 06/30/2024 | 03/31/2024 | 06/30/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 977.60K | 977.60K | 1.36M | 1.04M | 1.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.21M | 1.21M | 1.42M | 1.71M | 1.71M |
| Operating Income | -1.21M | -1.21M | -1.42M | -1.71M | -1.71M |
| Income Before Tax | -1.09M | -1.09M | -1.37M | -1.66M | -1.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.09M | -1.09M | -1.37M | -1.66M | -1.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -28.90K | -28.90K | 51.70K | 43.90K | 43.90K |
| Net Income | -1.12M | -1.12M | -1.32M | -1.61M | -1.61M |
| EBIT | -1.21M | -1.21M | -1.42M | -1.71M | -1.71M |
| EBITDA | -1.14M | -1.14M | -1.35M | -1.68M | -1.68M |
| EPS Basic | -0.09 | -0.09 | -0.10 | -0.12 | -0.12 |
| Normalized Basic EPS | -0.06 | -0.06 | -0.07 | -- | -- |
| EPS Diluted | -0.09 | -0.09 | -0.10 | -0.12 | -0.12 |
| Normalized Diluted EPS | -0.06 | -0.06 | -0.07 | -- | -- |
| Average Basic Shares Outstanding | 13.01M | 13.01M | 13.01M | 13.01M | 13.01M |
| Average Diluted Shares Outstanding | 13.01M | 13.01M | 13.01M | 13.01M | 13.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |